For the first time, American researchers have shown that sperm production can be stopped and fully restarted in male mice — without hormones, without permanent effects, and without harming offspring. The breakthrough, published in April 2026 C.E. in the Proceedings of the National Academy of Sciences, brings a long-sought goal in reproductive medicine meaningfully closer to reality.
At a glance
- Reversible male contraception: Cornell scientists used a small molecule called JQ1 to halt sperm production in male mice for three weeks, then stopped treatment — and within six weeks, normal sperm production returned completely.
- Nonhormonal approach: Unlike most contraceptive research, this method targets meiosis directly in the testis, leaving libido and secondary sex characteristics entirely unaffected.
- Healthy offspring: Mice that recovered fertility after treatment bred successfully, and their pups were also fertile — confirming no heritable damage from the intervention.
Why this matters
Right now, men have two main contraceptive options: condoms or vasectomy. Vasectomies are technically reversible through surgery, but the procedure is complex and success rates drop over time. No long-acting, fully reversible, nonhormonal option exists for men.
That gap carries real consequences. The global contraceptive burden falls disproportionately on women, many of whom face hormonal side effects ranging from mood changes to cardiovascular risk. Researchers have long hesitated to develop a male hormonal contraceptive for the same reasons. A safe, nonhormonal male option would shift that balance.
“We were really motivated to look for nonhormonal contraceptive targets in the testis,” said Paula Cohen, professor of genetics at Cornell’s College of Veterinary Medicine and director of the Cornell Reproductive Sciences Center. “Something that stops sperm production without affecting male libido and secondary sex characteristics.”
How the science works
Sperm production runs through three main stages. It begins with stem cells that replenish throughout a man’s life. Those cells then enter meiosis — the division process that halves the chromosome count to produce sex cells. After meiosis, a final stage called spermiogenesis shapes those cells into swimming sperm.
Cohen’s team targeted meiosis deliberately. Disrupting the stem cells would cause permanent infertility. Targeting spermiogenesis too late risked viable sperm surviving and escaping. The middle stage — meiosis, and specifically a phase called prophase 1 — turned out to be the right window.
The researchers used JQ1, a molecule originally developed to study cancer and inflammatory disease. It was never viable as a therapeutic drug because of neurological side effects, but it reliably disrupts prophase 1. That made it a precise research tool to prove the concept. After three weeks of JQ1 treatment, the mice produced no sperm at all. After treatment stopped, healthy sperm production resumed within six weeks. The mice then fathered fertile offspring with no abnormalities.
“Our study shows that mostly we recover normal meiosis and complete sperm function, and more importantly, that the offspring are completely normal,” Cohen said.
What comes next
JQ1 itself is not the end product — its neurological side effects rule that out. But it proved the principle. The team is now testing three new gene targets that, when disrupted, eliminate sperm production entirely in mice with no apparent health effects. The next step is confirming those targets can be switched on and off reversibly.
Cohen and her colleagues plan to launch a company within two years to advance the work toward human trials. If successful, the likely delivery format would be an injection every three months, or possibly a patch — designed to ensure consistent effectiveness. The Gates Foundation supported the research.
The study is co-first-authored by Stephanie Tanis and Leah Simon, both Ph.D. graduates from Cornell’s class of 2025, now postdoctoral researchers at the University of Colorado. Co-authors also include Jelena Lujic and Charles Danko from Cornell’s College of Veterinary Medicine.
It is worth being clear about where the science stands: this is a mouse study. The road from mice to a proven, approved human contraceptive is long, and many promising compounds fail to translate across species. Real-world efficacy, safety in humans, and delivery logistics all remain open questions.
Still, six years of careful work has produced something the field has never had before: a clear proof that meiosis in the testis can be targeted safely, stopped completely, and reversed without lasting harm. That is not a small thing. It is the foundation everything else gets built on.
Read more
For more on this story, see: Cornell University News
For more from Good News for Humankind, see:
- Renewables now make up at least 49% of global power capacity
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
Germany finishes 60-year project turning coal mines into a 23-lake district
Germany’s Lusatian Lakeland is now complete — a chain of 23 human-made lakes covering 14,000 hectares where open-cast coal mines once scarred the land between Berlin and Dresden. The final piece, Lake Sedlitz, opened to swimmers and boaters this April, and in June, five of the lakes will be linked by navigable canals into a continuous 5,000-hectare waterway. Engineers spent decades channeling river water into the old craters, securing embankments, and flushing out acid — work that would have taken nature a century. The region now welcomes around 800,000 overnight stays a year, with former miners finding work in hospitality…
-
Brazilian researchers find vitamin D boosts breast cancer chemo by 79%
Vitamin D may give breast cancer chemotherapy a meaningful boost, according to a new Brazilian trial in which 43% of women taking a daily supplement saw their tumors disappear completely, compared to 24% on a placebo. Researchers at São Paulo State University gave 80 patients a modest 2,000 IU dose alongside their standard pre-surgery chemo — a level safe enough for everyday use and cheap enough for almost anyone. Most women in the study were vitamin D-deficient to begin with, a pattern common in cancer patients worldwide. If larger trials confirm the finding, it points to something rare and hopeful…
-
Chinese solar exports double in last month to hit record high
China’s solar exports hit a record 68.03 gigawatts in March 2026, nearly doubling February’s volume as countries raced to replace disrupted Middle Eastern oil and gas. Fifty nations logged all-time-high imports of Chinese solar equipment that month, with African countries jumping 176% from February alone. Behind those numbers are governments that had been moving cautiously on renewables and suddenly found solar to be the fastest, cheapest answer on the table. Battery and electric vehicle shipments climbed alongside the panels, hinting at a clean-energy package moving together. The takeaway is hopeful even amid hard circumstances: when fossil fuels falter, the world…
